Generics Bulletin is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
Menu
My View
  • Edit
  • Add your favourite topics for quick access
Partnered Content
Meet the Team
Ask the Analyst
RSS Feeds
Subscribe
Advertise
Contact Us
FAQs
Reports Store
UsernamePublicRestriction
Tags:
Sales & Earnings Business Strategies Biosimilars

Sandoz Sets Forth On Quest To Raise Its Margins

  • News

Executive Summary

Sandoz is set to undergo a transformation in terms of operational efficiency, geographic footprint and portfolio offering in a bid to lift its operating margin from the mid-teens range towards 20%.
Table

View full table

Advertisement

Related Content

Scrip
Sandoz Head Francis To Leave Amid Move Towards Autonomy
Generics Bulletin
Sandoz Head Francis To Leave Amid Move Towards Autonomy
Generics Bulletin
Autonomous Sandoz Set To Be Tighter And Leaner
Generics Bulletin
Sandoz Will Differentiate To Serve A Different World
Generics Bulletin
US Court of Appeals Upholds Gilenya Compound Patent, Dealing A Blow To Ezra Ventures
Generics Bulletin
Sandoz starts with Zessly in Germany
Generics Bulletin
Sandoz drops rituximab after US seeks more data

Topics

What to read next

Advertisement
Tags:
Sales & Earnings Business Strategies Biosimilars
UsernamePublicRestriction

Register

GB140059

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By